These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 21102346)

  • 1. Solid hypervascular liver lesions: accurate identification of true benign lesions on enhanced dynamic and hepatobiliary phase magnetic resonance imaging after gadobenate dimeglumine administration.
    Morana G; Grazioli L; Kirchin MA; Bondioni MP; Faccioli N; Guarise A; Schneider G
    Invest Radiol; 2011 Apr; 46(4):225-39. PubMed ID: 21102346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of a novel time-efficient protocol for gadobenate dimeglumine (Gd-BOPTA)-enhanced liver magnetic resonance imaging.
    Schneider G; Altmeyer K; Kirchin MA; Seidel R; Grazioli L; Morana G; Saini S
    Invest Radiol; 2007 Feb; 42(2):105-15. PubMed ID: 17220728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The value of gadobenate dimeglumine-enhanced hepatobiliary-phase MR imaging for the differentiation of scirrhous hepatocellular carcinoma and cholangiocarcinoma with or without hepatocellular carcinoma.
    Jeon TY; Kim SH; Lee WJ; Lim HK
    Abdom Imaging; 2010 Jun; 35(3):337-45. PubMed ID: 19350315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Focal liver lesions: whether a standard dose (0.05 mmol/kg) gadobenate dimeglumine can provide the same diagnostic data as the 0.1 mmol/kg dose.
    Nural MS; Gokce E; Danaci M; Bayrak IK; Diren HB
    Eur J Radiol; 2008 Apr; 66(1):65-74. PubMed ID: 17555901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of portal venous and delayed phases of gadolinium-enhanced magnetic resonance imaging study of cirrhotic liver for the detection of contrast washout of hypervascular hepatocellular carcinoma.
    Cereser L; Furlan A; Bagatto D; Girometti R; Como G; Avellini C; Orsaria M; Zuiani C; Bazzocchi M
    J Comput Assist Tomogr; 2010; 34(5):706-11. PubMed ID: 20861773
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metastasis versus focal eosinophilic infiltration of the liver in patients with extrahepatic abdominal cancer: an evaluation with gadobenate dimeglumine-enhanced magnetic resonance imaging.
    Park MS; Kim MJ; Lim JS; Kim SH; Kim HS; Chung YE; Kim KW
    J Comput Assist Tomogr; 2009; 33(1):119-24. PubMed ID: 19188798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhancement of liver parenchyma after injection of hepatocyte-specific MRI contrast media: a comparison of gadoxetic acid and gadobenate dimeglumine.
    Filippone A; Blakeborough A; Breuer J; Grazioli L; Gschwend S; Hammerstingl R; Heinz-Peer G; Kittner T; Laghi A; Leen E; Lencioni R; Lucidarme O; Remplik P; Robinson PJ; Ruehm SG; Schaefer F; Stoupis C; Tombach B; Valette PJ; Zech CJ; Huppertz A
    J Magn Reson Imaging; 2010 Feb; 31(2):356-64. PubMed ID: 20099349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypointense hepatic lesions depicted on gadobenate dimeglumine-enhanced three-hour delayed hepatobiliary-phase MR imaging: differentiation between benignancy and malignancy.
    Hwang HS; Kim SH; Jeon TY; Choi D; Lee WJ; Lim HK
    Korean J Radiol; 2009; 10(3):294-302. PubMed ID: 19412518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of dysplastic nodule diagnosis in patients with liver cirrhosis on unenhanced and gadobenate dimeglumine-enhanced MRI with dynamic and hepatobiliary phase.
    Quaia E; De Paoli L; Pizzolato R; Angileri R; Pantano E; Degrassi F; Ukmar M; Cova MA
    AJR Am J Roentgenol; 2013 Mar; 200(3):553-62. PubMed ID: 23436844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical implication of small (<20 mm) enhancing hepatic nodules observed only during three-dimensional gadobenate dimeglumine-enhanced hepatic arterial-phase MRI of the hepatitis B virus-induced mild cirrhosis.
    Kim YK; Lee YH; Kwak HS; Kim CS; Han YM
    Clin Imaging; 2008; 32(6):453-9. PubMed ID: 19006774
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gadobenate dimeglumine-enhanced liver MR imaging in cirrhotic patients: quantitative and qualitative comparison of 1-hour and 3-hour delayed images.
    Jeong WK; Byun JH; Lee SS; Won HJ; Kim KW; Shin YM; Kim PN; Lee MG
    J Magn Reson Imaging; 2011 Apr; 33(4):889-97. PubMed ID: 21448954
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low dose gadobenate dimeglumine for imaging of chronic myocardial infarction in comparison with standard dose gadopentetate dimeglumine.
    Bauner KU; Reiser MF; Huber AM
    Invest Radiol; 2009 Feb; 44(2):95-104. PubMed ID: 19077911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection and characterization of focal hepatic lesions: comparative study of MDCT and gadobenate dimeglumine-enhanced MR imaging.
    Lee HY; Lee JM; Kim SH; Shin KS; Lee JY; Han JK; Choi BI
    Clin Imaging; 2008; 32(4):287-95. PubMed ID: 18603184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential conditions causing impairment of selective hepatobiliary enhancement of gadobenate dimeglumine-enhanced delayed magnetic resonance imaging.
    Kim H; Kim MJ; Park MS; Cha SW; Lim JS; Yoo HS; Kim KW
    J Comput Assist Tomogr; 2010 Jan; 34(1):113-20. PubMed ID: 20118733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gadobenate dimeglumine as a contrast agent for dynamic breast magnetic resonance imaging: effect of higher initial enhancement thresholds on diagnostic performance.
    Sardanelli F; Fausto A; Esseridou A; Di Leo G; Kirchin MA
    Invest Radiol; 2008 Apr; 43(4):236-42. PubMed ID: 18340247
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of hepatic hypovascular metastases: 3D gradient echo MRI using a hepatobiliary contrast agent.
    Choi JY; Choi JS; Kim MJ; Lim JS; Park MS; Kim JH; Chung YE
    J Magn Reson Imaging; 2010 Mar; 31(3):571-8. PubMed ID: 20187199
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the incidence of nephrogenic systemic fibrosis in patients with moderate renal insufficiency administered gadobenate dimeglumine for MRI.
    Bryant BJ; Im K; Broome DR
    Clin Radiol; 2009 Jul; 64(7):706-13. PubMed ID: 19520215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-dose gadobenate dimeglumine versus standard-dose gadopentate dimeglumine for delayed contrast-enhanced cardiac magnetic resonance imaging.
    Balci NC; Inan N; Anik Y; Erturk MS; Ural D; Demirci A
    Acad Radiol; 2006 Jul; 13(7):833-9. PubMed ID: 16777557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Contrast-enhanced sonography with SonoVue: enhancement patterns of benign focal liver lesions and correlation with dynamic gadobenate dimeglumine-enhanced MRI.
    Ricci P; Laghi A; Cantisani V; Paolantonio P; Pacella S; Pagliara E; Arduini F; Pasqualini V; Trippa F; Filpo M; Passariello R
    AJR Am J Roentgenol; 2005 Mar; 184(3):821-7. PubMed ID: 15728603
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimization of single injection liver arterial phase gadolinium enhanced MRI using bolus track real-time imaging.
    Sharma P; Kalb B; Kitajima HD; Salman KN; Burrow B; Ray GL; Martin DR
    J Magn Reson Imaging; 2011 Jan; 33(1):110-8. PubMed ID: 21182128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.